3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Carcinoma, Transitional Cell
15
Neoplasms
14
Ovarian Neoplasms
13
Carcinoma, Renal Cell
13
Urinary Bladder Neoplasms
12
Carcinoma, Merkel Cell
12
Squamous Cell Carcinoma of Head and Neck
11
Colorectal Neoplasms
8
Triple Negative Breast Neoplasms
7
Pancreatic Neoplasms
7
Neoplasm Metastasis
7
Melanoma
7
Stomach Neoplasms
6
Recurrence
5
Breast Neoplasms
5
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Lymphoma, Non-Hodgkin
2
Kidney Neoplasms
2
Kidney Diseases
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Ovarian Epithelial
2
Uveal Melanoma
1
Urothelial Cancer
1
Interventions
Brentuximab Vedotin
27
pembrolizumab
13
Nivolumab
11
Dacarbazine
8
Vinblastine
7
Doxorubicin
7
Gemcitabine
6
Bendamustine Hydrochloride
6
plerixafor
5
fludarabine
4
Rituximab
4
Granulocyte Colony-Stimulating Factor
4
Cyclophosphamide
4
Azacitidine
4
abexinostat
3
Melphalan
3
Filgrastim
3
Etoposide
3
Busulfan
3
Bleomycin
3
umbralisib
2
relatlimab
2
pegfilgrastim
2
mocetinostat
2
itacitinib
2
givinostat hydrochloride
2
givinostat
2
fludarabine phosphate
2
durvalumab
2
cc-486
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hodgkin Disease
×
avelumab
×
Clear all
NCT02603419
2020-04-24
JAVELIN HODGKINS
Pfizer
Phase 1
Terminated
34 enrolled
43 charts